within Pharmacolibrary.Drugs.ATC.A;

model A05AX03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.03333333333333333,
    adminDuration  = 600,
    adminMass      = 0.2,
    adminCount     = 1,
    Vd             = 0.03,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Cyclobutyrol is a synthetic choleretic agent once used for the treatment of gallbladder and bile duct disorders. It acts by stimulating bile secretion. Cyclobutyrol is no longer approved for use or marketed in most countries.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic studies describing cyclobutyrol’s ADME or kinetic parameters were identified in the literature as of June 2024. No parameters are available for population, sex, age, or disease-state differences.</p><h4>References</h4><ol><li><p>Monte, MJ, et al., &amp; Jimenez, R (1989). Inhibition of biliary cholesterol and phospholipid secretion during cyclobutyrol-induced hydrocholeresis. <i>The Biochemical journal</i> 263(2) 513–518. DOI:<a href=&quot;https://doi.org/10.1042/bj2630513&quot;>10.1042/bj2630513</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2574569/&quot;>https://pubmed.ncbi.nlm.nih.gov/2574569</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A05AX03;
